MX2018000464A - Procedimientos y composiciones para el diagnostico y para el tratamiento de adrenoleucodistrofia. - Google Patents

Procedimientos y composiciones para el diagnostico y para el tratamiento de adrenoleucodistrofia.

Info

Publication number
MX2018000464A
MX2018000464A MX2018000464A MX2018000464A MX2018000464A MX 2018000464 A MX2018000464 A MX 2018000464A MX 2018000464 A MX2018000464 A MX 2018000464A MX 2018000464 A MX2018000464 A MX 2018000464A MX 2018000464 A MX2018000464 A MX 2018000464A
Authority
MX
Mexico
Prior art keywords
adrenoleukodystrophy
treatment
diagnosis
compositions
methods
Prior art date
Application number
MX2018000464A
Other languages
English (en)
Inventor
Pujol Onofre Aurora
Portero Otín Manuel
Pamplona Gras Reinaldo
José López De Munain Arregi Adolfo
Jové Font Mariona
Fourcade Stephane
Original Assignee
Fundacio Inst Dinvestigacio Biomedica De Bellvitge Idibell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Inst Dinvestigacio Biomedica De Bellvitge Idibell filed Critical Fundacio Inst Dinvestigacio Biomedica De Bellvitge Idibell
Publication of MX2018000464A publication Critical patent/MX2018000464A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

La presente invención se refiere a un procedimiento de diagnóstico para adrenoleucodistrofia en un sujeto en base a la determinación de los niveles de diferentes marcadores. La invención también proporciona un procedimiento para monitorizar la progresión de una adrenoleucodistrofia, un procedimiento para monitorizar el efecto de un tratamiento de adrenoleucodistrofia y fingolimod, un análogo, metabolito o derivado del mismo, o una sal farmacéuticamente aceptable del mismo, para su uso en el tratamiento y/o prevención de una adrenoleucodistrofia.
MX2018000464A 2015-07-14 2016-07-14 Procedimientos y composiciones para el diagnostico y para el tratamiento de adrenoleucodistrofia. MX2018000464A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382366.1A EP3118621A1 (en) 2015-07-14 2015-07-14 Methods and compositions for the diagnosis and for the treatment of adrenoleukodystrophy
PCT/EP2016/066825 WO2017009437A1 (en) 2015-07-14 2016-07-14 Methods and compositions for the diagnosis and for the treatment of adrenoleukodystrophy

Publications (1)

Publication Number Publication Date
MX2018000464A true MX2018000464A (es) 2018-09-06

Family

ID=53776537

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000464A MX2018000464A (es) 2015-07-14 2016-07-14 Procedimientos y composiciones para el diagnostico y para el tratamiento de adrenoleucodistrofia.

Country Status (12)

Country Link
US (1) US20190010535A1 (es)
EP (2) EP3118621A1 (es)
JP (1) JP2018529081A (es)
KR (1) KR20180030074A (es)
CN (1) CN107923897A (es)
AU (1) AU2016293068A1 (es)
BR (1) BR112018000749A2 (es)
CA (1) CA2991586A1 (es)
CL (1) CL2018000078A1 (es)
HK (1) HK1253769A1 (es)
MX (1) MX2018000464A (es)
WO (1) WO2017009437A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
US20220072309A9 (en) * 2011-05-09 2022-03-10 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
WO2017127756A1 (en) 2016-01-20 2017-07-27 Setpoint Medical Corporation Control of vagal stimulation
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US11958805B2 (en) * 2017-03-09 2024-04-16 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
EP3668402A4 (en) 2017-08-14 2021-05-19 Setpoint Medical Corporation VAGUS NERVOUS STIMULATION PRE-SCREENING TEST
CN107362351B (zh) * 2017-09-04 2020-11-10 上海市儿童医院 Il-36r的拮抗剂在制备镇痛药物中的应用
WO2019068072A1 (en) * 2017-09-29 2019-04-04 The General Hospital Corporation METHODS OF IDENTIFICATION AND TREATMENT OF ADRENOMYELONEUROPATHY (AMN)
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
KR102252167B1 (ko) * 2018-11-22 2021-05-17 연세대학교 산학협력단 X-연관 부신백질이영양증 진단용 바이오마커 조성물
KR20230012585A (ko) 2020-05-21 2023-01-26 더 파인스타인 인스티튜츠 포 메디칼 리서치 미주 신경 자극을 위한 시스템들 및 방법들
FR3132910A1 (fr) * 2022-02-24 2023-08-25 Universite De Bourgogne Methodes pour le pronostic et le suivi des leucodystrophies peroxysomales

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1355193A (zh) * 2000-12-01 2002-06-26 复旦大学 一种新的多肽——肾上腺脑白质营养不良相关蛋白10.78和编码这种多肽的多核苷酸
WO2010097371A1 (en) 2009-02-24 2010-09-02 Novartis Ag Ceramide-analogous metabolites
US20100260755A1 (en) * 2009-04-09 2010-10-14 Medicinova, Inc. Ibudilast and immunomodulators combination
ES2377381B1 (es) * 2010-05-17 2013-03-14 Fundació Institut De Investigació Biomèdica De Bellvitge (Idibell) Uso de una combinación de n-acetil-cisteína y ácido lipoico para la preparación de un medicamento útil para el tratamiento de una enfermedad con daño axonal y lesiones oxidativas concomitantes.
JP2013533286A (ja) * 2010-07-30 2013-08-22 セントルイス ユニバーシティ 疼痛を治療する方法
WO2012112933A1 (en) * 2011-02-18 2012-08-23 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
EP2527344A1 (en) * 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
US10085955B2 (en) * 2013-01-08 2018-10-02 Pathologica Llc Methods and compositions for treatment of demyelinating diseases
KR20160061911A (ko) * 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과

Also Published As

Publication number Publication date
WO2017009437A1 (en) 2017-01-19
BR112018000749A2 (pt) 2018-09-04
HK1253769A1 (zh) 2019-07-05
EP3118621A1 (en) 2017-01-18
AU2016293068A1 (en) 2018-02-01
EP3322980A1 (en) 2018-05-23
US20190010535A1 (en) 2019-01-10
CA2991586A1 (en) 2017-01-19
EP3322980B1 (en) 2020-09-09
CL2018000078A1 (es) 2018-07-06
CN107923897A (zh) 2018-04-17
KR20180030074A (ko) 2018-03-21
JP2018529081A (ja) 2018-10-04

Similar Documents

Publication Publication Date Title
MX2018000464A (es) Procedimientos y composiciones para el diagnostico y para el tratamiento de adrenoleucodistrofia.
GB2569921A (en) Bisymmetric comparison of sub-epidermal moisture values
PH12016502256A1 (en) Medical use
SG10201903823QA (en) Methods and compositions relating to microbial treatment and diagnosis of disorders
EA201790398A1 (ru) Способы лечения заболевания печени
MX2022007221A (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos.
EP3149205A4 (en) Method for diagnostics, treatment and prevention of parkinson's disease
MX2015015907A (es) Metodo no invasivo objetivo para cuantificar el grado de comezon mediante el uso de mediciones psicofisiologicas.
WO2015197193A3 (en) New use for jnk inhibitor molecules for treatment of various diseases
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
PH12016502352A1 (en) Pharmaceutical composition
EP3432778C0 (en) DEVICE AND METHOD FOR LOCALIZING, MEASURING AND MONITORING INFLAMMATION OF SOFT TISSUE OF THE SKIN
TW201613578A (en) Pharmaceutical combinations
MA40535A (fr) Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90
EP3554353A4 (en) SYSTEM FOR CHARACTERIZING, DIAGNOSING AND TREATING A HEALTH CONDITION OF A PATIENT AND METHOD FOR USE THEREOF
WO2014200969A3 (en) Methods of treatment of cancer
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
TW201613569A (en) Composition consisting of kukoamine A and/or kukoamine B and method of using thereof
IL248935A0 (en) Diagnostic testing and treatment/prevention of Alzheimer's disease
MY186523A (en) Macrocyclic rip2 kinase inhibitors
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
EP3669880A4 (en) USE OF miR-18b IN THE PREVENTION, TREATMENT, OR DIAGNOSIS OF MUSCLE AND NEUROMUSCULAR DISEASE
WO2016097644A3 (fr) Marqueurs diagnostiques de la maladie de crohn
MX2017002628A (es) Dispositivo de visualizacion de imagenes sobre superficies de modelos anatomicos y metodo relacionado.
MA40574A (fr) Traitement de maladies fibrotiques